Osaka University-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Osaka University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013273
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Osaka University (OU) is an educational university that offers undergraduate and graduate courses. The university offers courses in dentistry, economics, engineering, engineering science, foreign studies, human sciences, law and politics, medicine, information science and technology, language and culture, pharmaceutical sciences and biosciences. Its research areas include microbial diseases, scientific and industrial research, protein research, social and economic, laser engineering, and joining and welding research. The university offers hospital services such as dental and university hospital services. It has operations in the US, Thailand, China and the Netherlands. OU is headquartered in Suita, Japan.

Osaka University – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Osaka University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Osaka University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Osaka University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Osaka University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Osaka University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Osaka University, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Mitsubishi Tanabe Pharma Forms Joint Venture with Research Foundation for Microbial Diseases of Osaka University 10
Oncolys Biopharma Enters into Research Agreement with Osaka University 11
BIKEN Enters into Distribution Agreement with Chiba Prefectural Institute of Health 12
Chugai Pharmaceutical Enters into Agreement with Osaka University 13
Takeda Pharma Enters Into Co-Marketing Agreement With Research Foundation For Microbial Diseases Of Osaka University 14
Takeda Pharma Enters Into Research Agreement With Osaka University 15
Licensing Agreements 16
NobelPharma Enters into Licensing Agreement with Osaka University 16
BIKEN Enters into Licensing Agreement with Osaka University 17
FunPep Enters into Licensing Agreement with Osaka University 18
Osaka University – Key Competitors 19
Osaka University – Key Employees 20
Osaka University – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 23
Government and Public Interest 23
Oct 26, 2017: Successful Cardiogenic Shock Treatment Using a Percutaneous Left Ventricular Assist Device 23
Aug 22, 2017: The Pancreas provides a potential drug candidate for brain disease 24
Dec 08, 2016: Role of protein in pancreatic secretion suggests potential method for treating diabetes 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Osaka University, Pharmaceuticals & Healthcare, Key Facts 2
Osaka University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Osaka University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Osaka University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Osaka University, Deals By Therapy Area, 2011 to YTD 2017 8
Osaka University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Mitsubishi Tanabe Pharma Forms Joint Venture with Research Foundation for Microbial Diseases of Osaka University 10
Oncolys Biopharma Enters into Research Agreement with Osaka University 11
BIKEN Enters into Distribution Agreement with Chiba Prefectural Institute of Health 12
Chugai Pharmaceutical Enters into Agreement with Osaka University 13
Takeda Pharma Enters Into Co-Marketing Agreement With Research Foundation For Microbial Diseases Of Osaka University 14
Takeda Pharma Enters Into Research Agreement With Osaka University 15
NobelPharma Enters into Licensing Agreement with Osaka University 16
BIKEN Enters into Licensing Agreement with Osaka University 17
FunPep Enters into Licensing Agreement with Osaka University 18
Osaka University, Key Competitors 19
Osaka University, Key Employees 20
Osaka University, Other Locations 21
Osaka University, Subsidiaries 21

★海外企業調査レポート[Osaka University-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • DigitalGlobe Inc:企業の戦略的SWOT分析
    DigitalGlobe Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • CESC Limited:企業の戦略・SWOT・財務分析
    CESC Limited - Strategy, SWOT and Corporate Finance Report Summary CESC Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • 1-800-FLOWERS.COM, Inc.:企業の戦略・SWOT・財務分析
    1-800-FLOWERS.COM, Inc. - Strategy, SWOT and Corporate Finance Report Summary 1-800-FLOWERS.COM, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Tata Motors Ltd (TATAMOTORS):企業の財務・戦略的SWOT分析
    Tata Motors Ltd (TATAMOTORS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Novosibirsk International Airport (Tolmachevo):企業の戦略・SWOT・財務情報
    Novosibirsk International Airport (Tolmachevo) - Strategy, SWOT and Corporate Finance Report Summary Novosibirsk International Airport (Tolmachevo) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Navitas Ltd:企業の戦略的SWOT分析
    Navitas Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Duro Dakovic Group Plc:企業の戦略・SWOT・財務情報
    Duro Dakovic Group Plc - Strategy, SWOT and Corporate Finance Report Summary Duro Dakovic Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Herantis Pharma Plc (HRTIS):企業の財務・戦略的SWOT分析
    Summary Herantis Pharma Plc (Herantis Pharma) operates as a drug development company that offers regenerative medicine for neurodegenerative diseases. The company's pipeline products include CDNF for amyotrophic lateral sclerosis, CDNF for Parkinson’s disease and lymfactin for secondary lymphedema. …
  • Land Securities Group Plc:企業のM&A・事業提携・投資動向
    Land Securities Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Land Securities Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Biocodex Inc-製薬・医療分野:企業M&A・提携分析
    Summary Biocodex Inc (Biocodex), a subsidiary of Biocodex is a manufacturer and distributor probiotic drug products. The company’s products include Saccharomyces boulardii CNCM I-745 that has a positive effect on the gut's microflora. It also provides Florastor, a yeast-based probiotic that helps ke …
  • Azul SA (AZUL):企業の財務・戦略的SWOT分析
    Azul SA (AZUL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Indigo Books & Music, Inc.:戦略・SWOT・企業財務分析
    Indigo Books & Music, Inc. - Strategy, SWOT and Corporate Finance Report Summary Indigo Books & Music, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Granules India Ltd (GRANULES):企業の財務・戦略的SWOT分析
    Granules India Ltd (GRANULES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Unum Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Unum Therapeutics Inc (Unum) is a cancer cell therapy company that discovers, develops, and commercializes novel antibody-coupled cellular immunotherapies. The company uses its proprietary Antibody-Coupled T-cell Receptor (ACTR) technology for discovering and developing new cellular immunoth …
  • Avillion LLP-製薬・医療分野:企業M&A・提携分析
    Summary Avillion LLP (Avillion) is a provider of drug development services. The company supports pharmaceutical and biotechnology companies to develop drug candidates without increasing the burden on them. It maintains a business model for the clinical development and regulatory approval of late sta …
  • Ocular Therapeutix Inc (OCUL):企業の財務・戦略的SWOT分析
    Summary Ocular Therapeutix Inc (Ocular Therapeutix), formerly I-Therapeutix Inc, is a biopharmaceutical company that discovers, develops and commercializes therapies for treating eye diseases. The company’s lead product candidate DEXTENZA is used for the treatment of post-surgical ocular inflammatio …
  • Biogen Inc (BIIB):企業の財務・戦略的SWOT分析
    Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Accent Group Ltd (AX1):企業の財務・戦略的SWOT分析
    Accent Group Ltd (AX1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Episurf Medical AB (EPIS B):企業の製品パイプライン分析2018
    Summary Episurf Medical AB (Episurf Medical), formerly Diamorph Medtech AB is a medical technology company that provides patient-specific treatments of painful joint injuries. The company offers diagnosis and design of implants and surgical instruments. Its products include Episealer Femoral Twin, E …
  • Verizon Connect:企業の戦略的SWOT分析
    Verizon Connect - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆